Amicus Therapeutics Completes Merger with BioMarin, Becomes Wholly-Owned Subsidiary
Summary
Amicus Therapeutics, Inc. has completed its merger with BioMarin Pharmaceutical Inc., becoming a wholly-owned subsidiary and terminating all public offerings of its securities.
Key Events
-
Merger Completion
Amicus Therapeutics, Inc. has completed its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., making Amicus a private entity.
-
Deregistration of Securities
As a direct result of the merger, Amicus has filed to deregister all previously registered but unsold securities, terminating all public offerings and sales.
Analysis
This POSASR filing confirms the completion of the merger between Amicus Therapeutics, Inc. and Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc. As a result, Amicus Therapeutics is now a private, wholly-owned subsidiary of BioMarin, and its public offerings of securities have been terminated. This marks the final step in the acquisition process, following recent regulatory clearances, and effectively ends Amicus's existence as an independent publicly traded company. The stock trading near its 52-week high prior to this completion suggests a favorable outcome for shareholders.
At the time of this filing, FOLD was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.50. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.